MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson’s Candidate, Stock Soars

On Thursday, MeiraGTx Holdings plc (NASDAQ:MGTX) announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development.

MeiraGTx will receive $200 million in upfront cash, and MeiraGTx and Hologen are forming a joint venture, Hologen Neuro AI Ltd.

Also Read: Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson’s Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints

Additionally, the joint venture, Hologen Neuro AI Ltd, will be funded with capital of up to …

Full story available on Benzinga.com